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Carbapenem-resistant Enterobacteriaceae (CRE) and extended-spectrum β-lactamase (ESBL)-producing Enterobacteriaceae ([@B1][@B2][@B3]) top the Centers for Disease Control and Prevention\'s list of major threats ([@B4]). Antibiotic resistance is increasing, likely due to the rise of ESBLs and CREs; they are often multidrug resistant (MDR), leaving few therapeutic options and highlighting the need for new agents to treat serious infections caused by these pathogens ([@B5]), namely, urinary tract infections, nosocomial pneumonia, bacteremia, and intraabdominal infections. The next-generation aminoglycoside plazomicin has been evaluated in two phase 3 clinical studies in patients with complicated urinary tract infections (cUTI) or acute pyelonephritis (AP) and in patients with bloodstream infections, hospital- and ventilator-associated bacterial pneumonia, or cUTI/AP due to CRE. Aminoglycosides are often used to treat CRE, as these drugs are bactericidal against these strains; however, increasing resistance due to the presence of genes encoding aminoglycoside-modifying enzymes (AMEs) has given clinicians pause ([@B6][@B7][@B8]), as these organisms typically carry multiple resistance determinants ([@B9], [@B10]). Plazomicin maintains activity against most aminoglycoside-resistant Enterobacteriaceae as it is not inactivated by plasmid-borne AMEs ([@B11]). It is also active *in vitro* against MDR Enterobacteriaceae clinical isolates, including ESBL-producing isolates and CRE. This study examined the bactericidal activities of plazomicin and comparator agents against MDR Enterobacteriaceae in minimum bactericidal concentration (MBC) and time-kill assays.

MDR Enterobacteriaceae isolates were acquired from IHMA (Schaumburg, IL) and were genetically characterized for resistance to aminoglycosides (Achaogen, South San Francisco, CA) and β-lactams (IHMA) (see Table S1 in the supplemental material); these isolates were resistant to currently used antibiotics, including aminoglycosides (amikacin and gentamicin), β-lactams (ceftazidime and meropenem), and a fluoroquinolone (levofloxacin). Escherichia coli ATCC 25922 served as the quality control strain. Plazomicin was provided by Achaogen as a stock solution in sterile distilled water (dH~2~O). The comparators meropenem (USP, Rockville, MD), tigecycline (Waterstone Technology, Carmel, IN), amikacin, colistin, gentamicin, levofloxacin, and ceftazidime (Sigma-Aldrich) were dissolved in accordance with Clinical and Laboratory Standards Institute (CLSI) guidelines ([@B12]).

The MIC and MBC values for plazomicin and comparators were determined by broth microdilution in accordance with CLSI guidelines ([@B12][@B13][@B14]). For MBC determinations, duplicate 10-μl aliquots from the MIC well and from three wells above the MIC were sampled for CFU enumeration. The MBC was defined as the concentration of drug that resulted in ≥3-log~10~ CFU/ml decrease (99.9% kill) after an overnight incubation. MBC:MIC ratios were determined, and MBC:MIC ratios of ≤4 were considered indicative of bactericidal activity ([@B15]).

The time-kill kinetics of plazomicin (at 2-, 4-, 8-, and 16-fold the MIC), amikacin, gentamicin, meropenem, and colistin (at 8-fold the MIC) against 10 isolates (three E. coli, including ATCC 25922, four Klebsiella spp., and three Enterobacter spp.) were determined per CLSI guidelines ([@B14]). For isolates with MIC values of \>8 μg/ml, a concentration of 64 μg/ml was used. After inoculation and sampling for a baseline viable count, flasks with the appropriate drug concentrations were incubated at 35°C with shaking. The flasks were sampled at specified time points for the determination of viable counts. Bactericidal activity was defined as a 3-log~10~ decrease in CFU/ml relative to the starting inoculum maintained through 24 h.

The MIC~50/90~ and MBC~50/90~ values, as well as the MBC:MIC ratios and percent susceptibilities overall and by species, for plazomicin and comparator agents are shown in [Table 1](#T1){ref-type="table"}. Against all isolates, plazomicin displayed an MIC~50/90~ of 0.5/2 μg/ml and an MBC~50/90~ of 0.5/4 μg/ml, with an MBC:MIC ratio of ≤4 for 29 of 30 isolates (96.7%). In contrast, amikacin and gentamicin both demonstrated an MIC~50/90~ value of 32/128 μg/ml against these isolates. Amikacin had an MBC~50/90~ of 64/256 μg/ml and an MBC:MIC ratio of ≤4 for 96.7% of isolates; gentamicin had an MBC~50/90~ of 64/\>512 μg/ml and an MBC:MIC ratio of ≤4 for 92.6% of isolates. As the majority of the isolates were resistant to these aminoglycosides, the MBCs for gentamicin and amikacin are not clinically relevant, despite the low MBC:MIC ratios.

###### 

Summary of the MIC and MBC values (μg/ml) and MBC:MIC ratios of plazomicin and other evaluated agents against Enterobacteriaceae

  Organism                                                  Agent[^*a*^](#T1F1){ref-type="table-fn"}   MIC             MBC           MBC:MIC ratio                                                                         
  --------------------------------------------------------- ------------------------------------------ --------------- ------------- --------------- ----- --------------- ------------- --------- ----------- ----------- ----------
  Enterobacteriaceae                                        PLZ                                        30              0.12 to 8     0.5/2           ---   30              0.12 to 8     0.5/4     30          29 (96.7)   1 (3.3)
  AMK                                                       30                                         1 to 256        32/128        30.0            30    2 to \>256      64/256        30        29 (96.7)   1 (3.3)     
  GEN                                                       30                                         0.25 to \>512   32/128        33.3            28    0.25 to \>512   64/\>512      27        25 (92.6)   2 (7.4)     
  CAZ                                                       30                                         0.5 to \>512    64/\>512      10.0            24    0.5 to \>512    128/\>512     21        21 (100)                
  MEM                                                       30                                         0.15 to 128     0.06/64       60.0            30    0.03 to 128     0.12/64       30        30 (100)                
  LVX                                                       30                                         0.03 to 256     16/64         30.0            30    0.03 to \>128   16/64         30        29 (96.7)   1 (3.3)     
  TIG                                                       30                                         0.12 to 8       0.5/4         80.0            30    0.25 to \>8     \>4/\>16      29        7 (24.1)    22 (75.9)   
  COL                                                       30                                         0.06 to \>32    0.12/0.25     93.3            28    0.06 to 0.5     0.12/0.5      28        28 (100)                
  E. coli                                                   PLZ                                        10              0.5 to 4      1/4             ---   10              0.5 to 8      1/4       10          9 (90.0)    1 (10.0)
  AMK                                                       10                                         1 to 256        32/128        30.0            10    2 to \>256      32/256        10        9 (90.0)    1 (10.0)    
  GEN                                                       10                                         0.25 to \>512   64/512        40.0            9     0.25 to \>512   64/---        8         8 (100)                 
  CAZ                                                       10                                         0.5 to \>512    64/\>512      20.0            7     0.5 to \>512    64/---        6         6 (100)                 
  MEM                                                       10                                         0.015 to 8      0.03/8        80.0            10    0.03 to 8       0.03/8        10        10 (100)                
  LVX                                                       10                                         0.03 to 64      16/32         20.0            10    0.03 to \>128   32/64         10        9 (90.0)    1 (10.0)    
  TIG                                                       10                                         0.12 to 1       0.25/1        100             10    0.25 to \>8     \>2/\>8       10        3 (30.0)    7 (70.0)    
  COL                                                       10                                         0.12 to 0.25    0.25/0.25     100             10    0.12 to 0.25    0.25/0.25     10        10 (100)                
  Klebsiella spp.                                           PLZ                                        8               0.25 to 8     0.5/---         ---   8               0.25 to 8     0.5/---   8           8 (100)     
  AMK                                                       8                                          16 to 256       32/---        50.0            8     16 to 256       32/---        8         8 (100)                 
  GEN                                                       8                                          2 to \>512      64/---        25.0            7     2 to 256        64/---        7         6 (85.7)    1 (14.3)    
  CAZ                                                       8                                          64 to \>512     128/---       0.0             6     2 to \>512      64/---        5         5 (100)                 
  MEM                                                       8                                          0.06 to 128     32/---        12.5            8     64 to \>512     32/---        8         8 (100)                 
  LVX                                                       8                                          0.5 to 256      16/---        25.0            8     0.06 to 128     16/---        8         8 (100)                 
  TIG                                                       8                                          0.5 to 8        2/---         50.0            8     \>4 to \>16     \>16/---      7         1 (14.3)    6 (85.7)    
  COL                                                       8                                          0.12 to \>32    0.12/---      75.0            6     0.12 to 0.5     0.12/---      6         6 (100)                 
  Enterobacter spp.                                         PLZ                                        10              0.25 to 2     0.5/1           ---   10              0.25 to 4     0.5/1     10          10 (100)    
  AMK                                                       10                                         4 to 128        16/64         50.0            10    4 to 256        16/128        10        10 (100)                
  GEN                                                       10                                         0.5 to 128      8/64          30.0            10    0.5 to \>512    8/256         10        9 (90.0)    1 (10.0)    
  CAZ                                                       10                                         4 to 512        64/512        10.0            10    8 to \>512      128/512       9         9 (100)                 
  MEM                                                       10                                         0.015 to 32     0.06/4        80.0            10    0.03 to 32      0.06/4        10        10 (100)                
  LVX                                                       10                                         0.03 to 32      1/32          50.0            10    0.03 to 64      1/32          10        10 (100)                
  TIG                                                       10                                         0.5 to 8        0.5/4         80.0            10    0.5 to \>16     \>4/16        10        3 (30.0)    7 (70.0)    
  COL                                                       10                                         0.06 to 0.12    0.12/0.12     100             10    0.06 to 0.12    0.12/0.12     10        10 (100)                
  Citrobacter freundii[^*d*^](#T1F4){ref-type="table-fn"}   PLZ                                        2               0.12 to 0.5                   ---   2               0.12 to 0.5             2           2 (100)     
  AMK                                                       2                                          32 to 256                     0.0             2     64 to \>512                   2         2 (100)                 
  GEN                                                       2                                          0.5 to 64                     50.0            2     0.5 to 64                     2         2 (100)                 
  CAZ                                                       2                                          \>32 to 512                   0.0             1     512                           1         1 (100)                 
  MEM                                                       2                                          0.03 to 64                    50.0            2     0.03 to 64                    2         2 (100)                 
  LVX                                                       2                                          0.5 to 32                     50.0            2     0.5 to 32                     2         2 (100)                 
  TIG                                                       2                                          0.5 to 2                      100             2     \>4 to \>16                   2                     2 (100)     
  COL                                                       2                                          0.12 to 0.25                  100             2     0.12 to 0.5                   2         2 (100)                 

PLZ, plazomicin; AMK, amikacin; GEN, gentamicin; CAZ, ceftazidime; MEM, meropenem; LVX, levofloxacin; TIG, tigecycline; COL, colistin.

%S, percent susceptibility using CLSI M100-S25 susceptibility breakpoints (FDA breakpoints applied for tigecycline).

Isolates with MIC/MBC values that were undefined/off scale were not included for analysis of MBC:MIC ratio, i.e., if the MIC value for an isolate fell outside the MIC testing range for an antibiotic.

Only MIC and MBC ranges are shown for C. freundii (MIC~50/90~ and MBC~50/90~ not applicable).

Ceftazidime and meropenem had MIC~50/90~ values of 64/\>512 and 0.06/64 μg/ml, respectively, against the tested isolates. The MBC~50/90~ for ceftazidime was 128/\>512 μg/ml; that for meropenem was 0.12/64 μg/ml, with MBC:MIC ratios of ≤4 for 100% of values. Levofloxacin had an MIC~50/90~ of 16/64 μg/ml and an MBC~50/90~ of 16/64 μg/ml, with an MBC:MIC ratio of ≤4 for 96.7% of isolates. Tigecycline and colistin had MIC~50/90~ values of 0.5/4 and 0.12/0.25 μg/ml, respectively, against these Enterobacteriaceae. Tigecycline was generally bacteriostatic by MBC, with an MBC~50/90~ of \>4/\>16 μg/ml and an MBC:MIC ratio of \>4 against 75.9% of isolates. Colistin was bactericidal with an MBC~50/90~ of 0.12/0.5 and an MBC:MIC ratio of ≤4 for all isolates.

Plazomicin and comparators were evaluated by a time-kill assay against a subset of isolates as shown in [Table 2](#T2){ref-type="table"}; the results for plazomicin are shown in [Fig. 1](#F1){ref-type="fig"}. A summary of the time-kill results for comparators is shown in Fig. S1. At ≥4-fold the MIC against the E. coli isolates ([Fig. 1a](#F1){ref-type="fig"}), plazomicin was rapidly bactericidal for up to 6 h, but there was regrowth at doses \<16-fold MIC through 24 h. Against ECO001/ATCC 25922, amikacin (through 24 h) and gentamicin (only to 6 h) showed cidal activity. Colistin showed rapid \>3-log~10~ CFU killing against all three strains out to 6 h and against the ECO1143 and ECO156 strains through 24 h. Against the three Klebsiella pneumoniae isolates, plazomicin demonstrated \>3-log~10~ CFU killing within 1 h at ≥4-fold the MIC through 24 h ([Fig. 1b](#F1){ref-type="fig"}). Amikacin and gentamicin showed rapid killing against KPN1158 but no activity against KPN1152; amikacin demonstrated killing against KPN1149 as well. Colistin was rapidly cidal only through 6 h against all three K. pneumoniae isolates. Plazomicin demonstrated 2-log~10~ to 3-log~10~ CFU killing by 6 h at all concentrations against the Klebsiella oxytoca isolate, similar to amikacin, which was bactericidal at 6 h; gentamicin was not bactericidal at any time point. Colistin showed bactericidal activity through 6 h against KOX1006 with regrowth at 24 h. Plazomicin demonstrated \>3-log~10~ killing against the Enterobacter aerogenes isolate EAE1025 at all concentrations through 6 h without regrowth through 24 h at concentrations ≥8-fold the MIC. Similarly, against the two Enterobacter cloacae isolates ECL1059 and ECL1060, plazomicin was bactericidal at concentrations ≥4-fold the MIC. Amikacin and gentamicin showed 3-log~10~ CFU killing through 6 and 24 h, respectively, against EAE1025 and ECL1060. For colistin, bactericidal activity was observed through 6 h for EAE1025, but cidality was observed for 4 h against ECL1059 and ECL1060.

###### 

Activity of plazomicin and comparators against isolates evaluated by time-kill

  Organism        Isolate ID[^*a*^](#T2F1){ref-type="table-fn"}                                                               AME and β-lactamase molecular summary                                        MIC (μg/ml)[^*b*^](#T2F2){ref-type="table-fn"}                           
  --------------- ----------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------- ------------------------------------------------ ------- ------- ------- ------
  E. coli         AECO001 (ATCC 25922)                                                                                                                                                                     0.5                                              1       0.25    0.03    0.25
  AECO1143        *aac*(3)-IIa; *aph*(3′)-VIa; *bla*~CTX-M-55~                                                                0.5                                                                          256                                              64      0.015   0.12    
  AECO1156        *aac*(3)-IIa; *aac*(6′)-Ib; *bla*~TEM-OSBL~; *bla*~CTX-M-15~                                                1                                                                            64                                               \>512   0.03    0.25    
  K. pneumoniae   AKPN1149                                                                                                    *aac*(3)-IVa; *aac*(6′)-Ib; *bla*~SHV-OSBL~; *bla*~TEM-OSBL~; *bla*~KPC-2~   0.25                                             32      64      128     0.12
  AKPN1152        *aac*(3)-IIa; *aac*(6′)-Ib; *aph*(3′)-VIa; *bla*~SHV-OSBL~; *bla*~TEM-OSBL~; bla~CTX-M-14~; *bla*~OXA-48~   0.25                                                                         256                                              128     32      0.12    
  AKPN1158        *aac*(6′)-Ib; *bla*~SHV-OSBL~; *bla*~TEM-OSBL~; *bla*~CTX-M-15~; *bla*~KPC-3~                               0.5                                                                          64                                               2       16      0.12    
  K. oxytoca      AKOX1006                                                                                                    *aac*(3)-Ia/d; *aac*(6′)-Ib; *bla*~SHV-5~; *bla*~TEM-OSBL~; *bla*~KPC-2~     1                                                64      128     16      0.12
  E. aerogenes    AEAE1025                                                                                                    *aac*(3)-Ia/d; *aac*(6′)-Ib                                                  0.5                                              16      8       0.06    0.12
  E. cloacae      AECL1059                                                                                                    *aac*(3)-IIa; *aph*(3′)-VIa                                                  0.5                                              64      128     0.015   0.12
  AECL1060        *aac*(6′)-Ib; *ant*(2″)-Ia; *bla*~SHV-12~; *bla*~ACT-7~                                                     0.5                                                                          16                                               32      32      0.12    

ID, identifier.

PLZ, plazomicin; AMK, amikacin; GEN, gentamicin; MEM, meropenem; COL, colistin.

![(a) Time-kill kinetics of plazomicin against E. coli. (b) Time-kill kinetics of plazomicin against K. pneumoniae. (c) Time-kill kinetics of plazomicin against Enterobacter spp. Black diamonds, growth control; gray X\'s, plazomicin at 2× MIC; circles, plazomicin at 4× MIC; triangles, plazomicin at 8× MIC; gray diamonds, plazomicin at 16× MIC. Upper horizontal dashed lines represent the 3-log~10~ CFU decrease from time zero (*t*~0~); lower dotted horizontal lines represent the limits of detection.](zac0081873600001){#F1}

Here, plazomicin demonstrated potent bactericidal activity against aminoglycoside- and β-lactam-resistant MDR Enterobacteriaceae isolates. By MBC~50/90~ and by MBC:MIC ratios, plazomicin and colistin were the most active bactericidal agents evaluated; tigecycline had potent activity by MIC but was largely bacteriostatic. In contrast, the high MBC~50/90~ values for the other antibiotics evaluated reflected their decreased activities against this panel of isolates.

Time-kill assays confirmed the potent bactericidal activity of plazomicin, where rapid and sustained 3-log killing at concentrations at or greater than 4-fold the MIC was observed. Plazomicin displays potent *in vitro* activity that further translates to rapid and sustained bacterial killing at lower concentrations than comparator agents in this study. Bactericidal activity at lower concentrations could be an advantage for a new antibacterial agent, as this prevents bacterial regrowth and presumably resistance emergence ([@B16]). That this set of organisms is MDR highlights the clinical potential of plazomicin against isolates with challenging resistance phenotypes.
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